To identify the genetic determinants underlying sensitivity to FGFR-targeted therapy, Z. Yang et al. performed a CRISPR/Cas9 kinome (human protein kinases) knockout in FGFR1-enhanced lung cancer cells [50]. This evidence concerns the gene FGFR1 and lung cancer.